The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PERCEPTION: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer— A NOGGO trial.
 
Jacek P. Grabowski
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; RIEMSER
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; RIEMSER
Speakers' Bureau - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca; GlaxoSmithKline; MSD; RIEMSER
 
Lea-Jean Pietzke
No Relationships to Disclose
 
Dario Zocholl
No Relationships to Disclose
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Florian Heitz
Honoraria - AstraZeneca; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novocure; PharmaMar; Roche
Research Funding - Amedes (Inst); AstraZeneca (Inst)
 
Radoslav Chekerov
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro